Association between the coexistence of chronic kidney disease and sarcopenia with cardiovascular disease and mortality DOI Creative Commons

Lijun Jiang,

Liangliang Xu, Wen Sun

и другие.

Aging Clinical and Experimental Research, Год журнала: 2025, Номер 37(1)

Опубликована: Март 17, 2025

Abstract Background Chronic kidney disease (CKD) and sarcopenia are independently associated with adverse cardiovascular mortality outcomes. However, the combined impact of CKD remains poorly understood. To evaluate effects on (CVD) risks in a large population-based cohort. Methods We analyzed data from 477,380 participants UK Biobank, categorized into four groups based presence or absence sarcopenia: Non-CKD Non-Sarcopenia, Sarcopenia, Sarcopenia. Cox proportional hazards models estimated hazard ratios (HRs) 95% confidence intervals (CIs) for CVD Kaplan-Meier survival analyses compared event-free across groups. Results Participants both exhibited highest all outcomes to those without either condition. For stroke, adjusted HR was 2.17 (95% CI: 1.65–2.86), significantly higher than alone (HR: 1.69, 1.47–1.94) 1.28, 1.03–1.59). Similar trends were observed coronary artery (CAD) heart failure (HF), HRs 1.53 1.38–1.69) 2.22 1.99–2.47), respectively, CKD-sarcopenia group. The coexistence also elevated all-cause 2.59, 2.17–3.09) cardiovascular-specific 4.08, 2.95–5.66). Conclusion amplifies mortality, highlighting need integrated management strategies address this high-risk population. Early detection tailored interventions targeting these dual risk factors may mitigate their compounded burden improve clinical

Язык: Английский

Association between the coexistence of chronic kidney disease and sarcopenia with cardiovascular disease and mortality DOI Creative Commons

Lijun Jiang,

Liangliang Xu, Wen Sun

и другие.

Aging Clinical and Experimental Research, Год журнала: 2025, Номер 37(1)

Опубликована: Март 17, 2025

Abstract Background Chronic kidney disease (CKD) and sarcopenia are independently associated with adverse cardiovascular mortality outcomes. However, the combined impact of CKD remains poorly understood. To evaluate effects on (CVD) risks in a large population-based cohort. Methods We analyzed data from 477,380 participants UK Biobank, categorized into four groups based presence or absence sarcopenia: Non-CKD Non-Sarcopenia, Sarcopenia, Sarcopenia. Cox proportional hazards models estimated hazard ratios (HRs) 95% confidence intervals (CIs) for CVD Kaplan-Meier survival analyses compared event-free across groups. Results Participants both exhibited highest all outcomes to those without either condition. For stroke, adjusted HR was 2.17 (95% CI: 1.65–2.86), significantly higher than alone (HR: 1.69, 1.47–1.94) 1.28, 1.03–1.59). Similar trends were observed coronary artery (CAD) heart failure (HF), HRs 1.53 1.38–1.69) 2.22 1.99–2.47), respectively, CKD-sarcopenia group. The coexistence also elevated all-cause 2.59, 2.17–3.09) cardiovascular-specific 4.08, 2.95–5.66). Conclusion amplifies mortality, highlighting need integrated management strategies address this high-risk population. Early detection tailored interventions targeting these dual risk factors may mitigate their compounded burden improve clinical

Язык: Английский

Процитировано

0